Archive Newsletter

31. 05.26.26 -- Why Material Definitions Matter In Cell And Gene Therapy 5/26/2026
    05/26/26 Cell & Gene Newsletter
32. 05.26.26 -- Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease 5/26/2026
    05/26/26 Cell & Gene Newsletter
33. 05.22.26 -- Scaling RNA & LNP Manufacturing With Smarter Analytics 5/22/2026
    05/22/26 Cell & Gene Newsletter
34. 05.22.26 -- Inside March Biosciences' CD5-Targeting CAR-T Approach 5/22/2026
    05/22/26 Cell & Gene Newsletter
35. 05.21.26 -- Advancing Bioprocessing: Perfusion And Process Intensification Across Modalities 5/21/2026

    05/21/26 Cell & Gene Newsletter

36. 05.21.26 -- Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/21/2026
    05/21/26 Cell & Gene Newsletter
37. 05.20.26 -- Streamlined Lentiviral Characterization And QC With Digital PCR 5/20/2026

    05/20/26 Cell & Gene Newsletter

38. 05.20.26 -- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem 5/20/2026
    05/20/26 Cell & Gene Newsletter
39. 05.19.26 -- Building Integrated cGMP Systems For Autologous Cell Therapies With MassGen's Tatyana Matveeva, Ph.D. 5/19/2026
    05/19/26 Cell & Gene Newsletter
40. Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness 5/19/2026

    [UNSCHEDULED]